Novolog (Pharm-Up 1966) Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was ILS 1,643.49 million compared to ILS 1,507.95 million a year ago. Net loss was ILS 42 million compared to net income of ILS 47.51 million a year ago.

Basic loss per share from continuing operations was ILS 0.082 compared to basic earnings per share from continuing operations of ILS 0.094 a year ago. Diluted loss per share from continuing operations was ILS 0.082 compared to diluted earnings per share from continuing operations of ILS 0.092 a year ago.